The Filings Report

Repligen Corp

RGENNasdaqCIK 730272Healthcare / Biotechnologyfiscal year ends December65 quarters since 2010

Revenue, Q3 FY2026
$209M
+10.9% on Q3 FY2025
Net income
−$38M
−357.7% on Q3 FY2025
Free cash flow
$38M
−12.1% on Q3 FY2025
Diluted EPS
$-0.68
−361.5% on Q3 FY2025
Revenue, TTM
$806M
trailing four quarters
Net margin, TTM
-1.5%
net income −$12M
Free cash flow, TTM
$107M
$130M less $23M capex
Cash and equivalents
$727M
long-term debt $556M, Sep 30, 2026
Shares, 12-month change
+13.6%
64M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$11.1B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 30, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Repligen Corp reported revenue of $209M, +10.9% on Q3 FY2025, and net loss of $38M (−357.7%). Operating margin was −14.1%. Free cash flow, operating cash flow less capital expenditures, was $38M ($43M less $5M). Diluted earnings per share were $-0.68.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 30, 2026.

Revenue and net incomeRevenueNet income
−$100M$0$100M$200M$300MQ4'22, Revenue: $187MQ4'22, Net income: $49MQ4'22Q1'23, Revenue: $165MQ1'23, Net income: $15MQ1'23Q2'23, Revenue: $159MQ2'23, Net income: $20MQ2'23Q3'23, Revenue: $141MQ3'23, Net income: $17MQ3'23Q4'23, Revenue: $167MQ4'23, Net income: −$16MQ4'23Q1'24, Revenue: $153MQ1'24, Net income: $3MQ1'24Q2'24, Revenue: $159MQ2'24, Net income: $6MQ2'24Q3'24, Revenue: $155MQ3'24, Net income: −$654KQ3'24Q4'24, Revenue: $168MQ4'24, Net income: −$34MQ4'24Q1'25, Revenue: $169MQ1'25, Net income: $6MQ1'25Q2'25, Revenue: $182MQ2'25, Net income: $15MQ2'25Q3'25, Revenue: $189MQ3'25, Net income: $15MQ3'25Q4'25, Revenue: $198MQ4'25, Net income: $13MQ4'25Q1'26, Revenue: $194MQ1'26, Net income: $8MQ1'26Q2'26, Revenue: $204MQ2'26, Net income: $5MQ2'26Q3'26, Revenue: $209MQ3'26, Net income: −$38MQ3'26−$100M$0$100M$200M$300MQ4'22, Revenue: $187MQ4'22, Net income: $49MQ1'23, Revenue: $165MQ1'23, Net income: $15MQ1'23Q2'23, Revenue: $159MQ2'23, Net income: $20MQ3'23, Revenue: $141MQ3'23, Net income: $17MQ3'23Q4'23, Revenue: $167MQ4'23, Net income: −$16MQ1'24, Revenue: $153MQ1'24, Net income: $3MQ1'24Q2'24, Revenue: $159MQ2'24, Net income: $6MQ3'24, Revenue: $155MQ3'24, Net income: −$654KQ3'24Q4'24, Revenue: $168MQ4'24, Net income: −$34MQ1'25, Revenue: $169MQ1'25, Net income: $6MQ1'25Q2'25, Revenue: $182MQ2'25, Net income: $15MQ3'25, Revenue: $189MQ3'25, Net income: $15MQ3'25Q4'25, Revenue: $198MQ4'25, Net income: $13MQ1'26, Revenue: $194MQ1'26, Net income: $8MQ1'26Q2'26, Revenue: $204MQ2'26, Net income: $5MQ3'26, Revenue: $209MQ3'26, Net income: −$38MQ3'26

Net income losses drawn in red.

Free cash flow
$0$20M$40M$60MQ4'22, Free cash flow: $41MQ4'22Q1'23, Free cash flow: $3MQ1'23Q2'23, Free cash flow: $26MQ2'23Q3'23, Free cash flow: $31MQ3'23Q4'23, Free cash flow: $18MQ4'23Q1'24, Free cash flow: $36MQ1'24Q2'24, Free cash flow: $37MQ2'24Q3'24, Free cash flow: $42MQ3'24Q4'24, Free cash flow: $34MQ4'24Q1'25, Free cash flow: $11MQ1'25Q2'25, Free cash flow: $22MQ2'25Q3'25, Free cash flow: $43MQ3'25Q4'25, Free cash flow: $18MQ4'25Q1'26, Free cash flow: $24MQ1'26Q2'26, Free cash flow: $27MQ2'26Q3'26, Free cash flow: $38MQ3'26$0$20M$40M$60MQ4'22, Free cash flow: $41MQ1'23, Free cash flow: $3MQ1'23Q2'23, Free cash flow: $26MQ3'23, Free cash flow: $31MQ3'23Q4'23, Free cash flow: $18MQ1'24, Free cash flow: $36MQ1'24Q2'24, Free cash flow: $37MQ3'24, Free cash flow: $42MQ3'24Q4'24, Free cash flow: $34MQ1'25, Free cash flow: $11MQ1'25Q2'25, Free cash flow: $22MQ3'25, Free cash flow: $43MQ3'25Q4'25, Free cash flow: $18MQ1'26, Free cash flow: $24MQ1'26Q2'26, Free cash flow: $27MQ3'26, Free cash flow: $38MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$250M$500M$750M$1.0BQ4'22, Cash and equivalents: $523MQ4'22Q1'23, Cash and equivalents: $517MQ1'23Q2'23, Cash and equivalents: $604MQ2'23Q3'23, Cash and equivalents: $631MQ3'23Q4'23, Cash and equivalents: $751MQ4'23Q1'24, Cash and equivalents: $781MQ1'24Q2'24, Cash and equivalents: $809MQ2'24Q3'24, Cash and equivalents: $784MQ3'24Q4'24, Cash and equivalents: $757MQ4'24, Long-term debt: $526MQ4'24Q1'25, Cash and equivalents: $697MQ1'25Q2'25, Cash and equivalents: $709MQ2'25Q3'25, Cash and equivalents: $749MQ3'25, Long-term debt: $538MQ3'25Q4'25, Cash and equivalents: $566MQ4'25, Long-term debt: $542MQ4'25Q1'26, Cash and equivalents: $583MQ1'26, Long-term debt: $547MQ1'26Q2'26, Cash and equivalents: $607MQ2'26, Long-term debt: $551MQ2'26Q3'26, Cash and equivalents: $727MQ3'26, Long-term debt: $556MQ3'26$0$250M$500M$750M$1.0BQ4'22, Cash and equivalents: $523MQ1'23, Cash and equivalents: $517MQ1'23Q2'23, Cash and equivalents: $604MQ3'23, Cash and equivalents: $631MQ3'23Q4'23, Cash and equivalents: $751MQ1'24, Cash and equivalents: $781MQ1'24Q2'24, Cash and equivalents: $809MQ3'24, Cash and equivalents: $784MQ3'24Q4'24, Cash and equivalents: $757MQ4'24, Long-term debt: $526MQ1'25, Cash and equivalents: $697MQ1'25Q2'25, Cash and equivalents: $709MQ3'25, Cash and equivalents: $749MQ3'25, Long-term debt: $538MQ3'25Q4'25, Cash and equivalents: $566MQ4'25, Long-term debt: $542MQ1'26, Cash and equivalents: $583MQ1'26, Long-term debt: $547MQ1'26Q2'26, Cash and equivalents: $607MQ2'26, Long-term debt: $551MQ3'26, Cash and equivalents: $727MQ3'26, Long-term debt: $556MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Repligen Corp income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Mar 14, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue209204194198189182169168+10.9%
Cost of revenue98948697888978129+11.4%
Gross profit—————————
Research and development1414141414141212+1.8%
Selling, general and administrative8477777574717160+13.5%
Operating income(30)14161817147(37)−275.6%
Other income (expense)30(14)1041(2)+854.0%
Pretax income(27)1421917188(39)−256.7%
Income tax129(7)6232(5)+428.1%
Net income(38)581315156(34)−357.7%
Diluted EPS ($)(0.68)0.090.15—0.260.260.10—−361.5%
Diluted shares (millions)575757—575757——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Repligen Corp balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Mar 14, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents727607583566749709697757−2.9%
Short-term investments136204202202———0—
Total current assets1,2421,2011,1611,1371,0961,0571,0321,066+13.3%
Total assets2,9262,9502,9312,9502,9242,9022,8522,830+0.1%
Total current liabilities126133126136131123152127−4.2%
Long-term debt556551547542538——526+3.3%
Total liabilities835838825844841840867857−0.7%
Stockholders’ equity2,0922,1122,1052,1062,0832,0621,9851,973+0.4%
Shares outstanding (millions)6456565656565656—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Repligen Corp cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Mar 14, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow4333282648291539−10.4%
Capital expenditures55585746+5.2%
Free cash flow (CFO − capex)3827241843221134−12.1%
Depreciation and amortization1919202020201918−4.4%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Repligen Corp income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Mar 14, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Mar 17, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 15, 2012
Revenue73863463280267136627019414110584646862—
Cost of revenue352360354346279157119876747—————
Gross profit———————————————
Research and development54434344342019169766710—
Selling, general and administrative2912632192161841209666523125171313—
Operating income55(35)48225167703626141614112311—
Other income (expense)789(6)(14)(11)(10)(5)(7)(4)0000—
Pretax income62(27)5721915459262171213112311(2)
Income tax13(2)213325(1)55(21)0437(3)0
Net income49(26)361861286021172812981614(2)
Diluted EPS ($)0.86(0.46)0.633.242.241.110.440.370.720.340.280.250.500.45—
Diluted shares (millions)57*56*56*57*57*54*49453934*34333231—

Balance sheet

Repligen Corp balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Mar 14, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Mar 17, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 15, 2012
Cash and equivalents5667577515236047175281941741225435402911
Short-term investments2020—————00———221115
Total current assets1,1371,0661,11199893290264227624318410381866647
Total assets2,9502,8302,8312,5322,3581,9031,4007757442891461281199776
Total current liabilities136127165404375319481302521191111117
Long-term debt542526—————————————
Total liabilities844857866621608374340159152——————
Stockholders’ equity2,1061,9731,9651,9111,7501,5291,060616592169123112848466
Shares outstanding (millions)565656565555524444343333323131

Cash flow statement

Repligen Corp cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Mar 14, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Mar 17, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 15, 2012
Operating cash flow117175114172119636733178——2613—
Capital expenditures2426368567221911543651—
Free cash flow (CFO − capex)94150788752404922123——2112—
Depreciation and amortization79706951382721161155434—
Share repurchases001400——————————
Dividends paid———————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$6M
7 sales by 1 insider; officers and directors $6M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$15M
25 sales by 5 insiders; officers and directors $15M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 6, 2026Douglass Brian RobbCHIEF PRODUCT OFFICERaward700$0.00—8,685Oct 8, 2026
Oct 5, 2026Loeillot OlivierChief Executive Officer, Directoropen-market sale10b5-11,333$178.75$238K45,788Oct 6, 2026
Oct 5, 2026Loeillot OlivierChief Executive Officer, Directoroption exercise4,202$154.96$651K49,990Oct 6, 2026
Oct 5, 2026Loeillot OlivierChief Executive Officer, Directoropen-market sale10b5-14,202$190.00$798K45,788Oct 6, 2026
Oct 2, 2026Loeillot OlivierChief Executive Officer, Directortax withholding1,248$181.70$227K47,121Oct 5, 2026
Sep 25, 2026Garland Jason KCFOtax withholding421$189.68$80K18,408Sep 28, 2026
Sep 24, 2026Loeillot OlivierChief Executive Officer, Directoroption exercise8,404$154.96$1M56,773Sep 25, 2026
Sep 24, 2026Loeillot OlivierChief Executive Officer, Directoropen-market sale10b5-18,404$190.00$2M48,369Sep 25, 2026
Sep 24, 2026Loeillot OlivierChief Executive Officer, Directoroption exercise4,542$155.38$706K52,911Sep 25, 2026
Sep 24, 2026Loeillot OlivierChief Executive Officer, Directoropen-market sale10b5-14,542$190.00$863K48,369Sep 25, 2026
Sep 21, 2026Loeillot OlivierChief Executive Officer, Directoroption exercise5,426$141.79$769K53,795Sep 22, 2026
Sep 21, 2026Loeillot OlivierChief Executive Officer, Directoropen-market sale10b5-15,426$180.00$977K48,369Sep 22, 2026
Sep 4, 2026Loeillot OlivierChief Executive Officer, Directoropen-market sale10b5-13,035$165.90$504K48,369Sep 8, 2026
Sep 3, 2026Loeillot OlivierChief Executive Officer, Directortax withholding2,842$169.61$482K51,404Sep 8, 2026
Sep 1, 2026Hughes ViolettaCHIEF ACCOUNTING OFFICERtax withholding277$170.02$47K6,331Sep 2, 2026
Aug 20, 2026Loeillot OlivierChief Executive Officer, Directoroption exercise5,426$141.79$769K59,672Aug 21, 2026
Aug 20, 2026Loeillot OlivierChief Executive Officer, Directoropen-market sale10b5-15,426$180.00$977K54,246Aug 21, 2026
Jul 16, 2026Garland Jason KCFOopen-market sale10b5-1530$150.00$80K18,829Jul 17, 2026
Jun 25, 2026Garland Jason KCFOopen-market sale10b5-1733$145.00$106K19,359Jun 26, 2026
May 14, 2026Madaus Martin DDirectoraward995$0.00—6,581May 18, 2026
May 14, 2026Konstantinov KonstantinDirectoraward995$0.00—3,889May 18, 2026
May 14, 2026Eglinton Manner CarrieDirectoraward995$0.00—5,461May 18, 2026
May 14, 2026Mhatre RohinDirectoraward995$0.00—5,014May 18, 2026
May 14, 2026Pax MargaretDirectoraward995$0.00—3,011May 18, 2026
May 14, 2026Muir Glenn PDirectoraward995$0.00—40,051May 18, 2026

Full insider history for Repligen Corp, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held RGEN in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded RGEN by quarter.

FundManagerQuarterValueSharesWeightMove
Duquesne Family OfficeStanley DruckenmillerQ2 2026$11M77,4000.20%new
Baron Capital GroupRon BaronQ2 2026$102M748,4660.15%added +36.5%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
REPLIGEN CORP, CIK 730272 on EDGAR
Extract generated
November 4, 2026
Withheld
4 line-years whose four quarters do not sum to the filed year: net income FY2011, pretax income FY2011, other income FY2016, other income FY2017
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerIncludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): InvestmentIncomeNonoperating, NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/RGEN.json